Cargando…
Impact of lipid disorders on mortality among Saudi patients with heart failure
BACKGROUND: Dyslipidemia, a known cardiovascular risk factor, is extremely common among Saudis, both adults and children. The impact, however, of dyslipidemia and several other lipid disorders in patients with congestive heart failure in this particular population has not been documented. This study...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392377/ https://www.ncbi.nlm.nih.gov/pubmed/25870502 http://dx.doi.org/10.1016/j.jsha.2014.12.003 |
_version_ | 1782365970419941376 |
---|---|
author | Al Qahtani, M. Al Backer, T. Al Anazi, T. Al Johani, N. Binsalih, S. AlGobain, M. Alshammari, H. |
author_facet | Al Qahtani, M. Al Backer, T. Al Anazi, T. Al Johani, N. Binsalih, S. AlGobain, M. Alshammari, H. |
author_sort | Al Qahtani, M. |
collection | PubMed |
description | BACKGROUND: Dyslipidemia, a known cardiovascular risk factor, is extremely common among Saudis, both adults and children. The impact, however, of dyslipidemia and several other lipid disorders in patients with congestive heart failure in this particular population has not been documented. This study aims to fill the gap. METHODS: This retrospective, single center study was conducted at King Abdulaziz Medical City, Riyadh, Saudi Arabia. Of the 500 cases seen during the period between 2002 and 2008, 392 were included in the study. Charts were reviewed and information on medical history, medications, and lipid status were documented. RESULTS: Low HDL-cholesterol level was the most common lipid disorder with 82.9%, followed by hypertriglyceridemia (35.2%), atherogenic dyslipidemia (27.8%), and hypercholesterolemia (9.2%). Diabetes mellitus was the single most significant predictor of mortality (p = 0.001). Among the lipid disorders, only low levels of HDL-cholesterol contributed to significant mortality risk [OR 1.29 (Confidence Interval 1.04–1.59) (p-value < 0.01)] adjusted for age, gender and statin use. CONCLUSION: The results of this study suggest that emphasis should be on the elevation of HDL-cholesterol levels among subjects with congestive heart failure, without compromising any ongoing management of LDL-lowering drugs. Management should not be limited to conventional statin use and should promote other treatments to elevate HDL-cholesterol levels. |
format | Online Article Text |
id | pubmed-4392377 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-43923772015-04-13 Impact of lipid disorders on mortality among Saudi patients with heart failure Al Qahtani, M. Al Backer, T. Al Anazi, T. Al Johani, N. Binsalih, S. AlGobain, M. Alshammari, H. J Saudi Heart Assoc Full Length Article BACKGROUND: Dyslipidemia, a known cardiovascular risk factor, is extremely common among Saudis, both adults and children. The impact, however, of dyslipidemia and several other lipid disorders in patients with congestive heart failure in this particular population has not been documented. This study aims to fill the gap. METHODS: This retrospective, single center study was conducted at King Abdulaziz Medical City, Riyadh, Saudi Arabia. Of the 500 cases seen during the period between 2002 and 2008, 392 were included in the study. Charts were reviewed and information on medical history, medications, and lipid status were documented. RESULTS: Low HDL-cholesterol level was the most common lipid disorder with 82.9%, followed by hypertriglyceridemia (35.2%), atherogenic dyslipidemia (27.8%), and hypercholesterolemia (9.2%). Diabetes mellitus was the single most significant predictor of mortality (p = 0.001). Among the lipid disorders, only low levels of HDL-cholesterol contributed to significant mortality risk [OR 1.29 (Confidence Interval 1.04–1.59) (p-value < 0.01)] adjusted for age, gender and statin use. CONCLUSION: The results of this study suggest that emphasis should be on the elevation of HDL-cholesterol levels among subjects with congestive heart failure, without compromising any ongoing management of LDL-lowering drugs. Management should not be limited to conventional statin use and should promote other treatments to elevate HDL-cholesterol levels. Elsevier 2015-04 2014-12-23 /pmc/articles/PMC4392377/ /pubmed/25870502 http://dx.doi.org/10.1016/j.jsha.2014.12.003 Text en © 2015 Production and hosting by Elsevier B.V. on behalf of King Saud University. http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/). |
spellingShingle | Full Length Article Al Qahtani, M. Al Backer, T. Al Anazi, T. Al Johani, N. Binsalih, S. AlGobain, M. Alshammari, H. Impact of lipid disorders on mortality among Saudi patients with heart failure |
title | Impact of lipid disorders on mortality among Saudi patients with heart failure |
title_full | Impact of lipid disorders on mortality among Saudi patients with heart failure |
title_fullStr | Impact of lipid disorders on mortality among Saudi patients with heart failure |
title_full_unstemmed | Impact of lipid disorders on mortality among Saudi patients with heart failure |
title_short | Impact of lipid disorders on mortality among Saudi patients with heart failure |
title_sort | impact of lipid disorders on mortality among saudi patients with heart failure |
topic | Full Length Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4392377/ https://www.ncbi.nlm.nih.gov/pubmed/25870502 http://dx.doi.org/10.1016/j.jsha.2014.12.003 |
work_keys_str_mv | AT alqahtanim impactoflipiddisordersonmortalityamongsaudipatientswithheartfailure AT albackert impactoflipiddisordersonmortalityamongsaudipatientswithheartfailure AT alanazit impactoflipiddisordersonmortalityamongsaudipatientswithheartfailure AT aljohanin impactoflipiddisordersonmortalityamongsaudipatientswithheartfailure AT binsalihs impactoflipiddisordersonmortalityamongsaudipatientswithheartfailure AT algobainm impactoflipiddisordersonmortalityamongsaudipatientswithheartfailure AT alshammarih impactoflipiddisordersonmortalityamongsaudipatientswithheartfailure |